Provectus Biopharmaceuticals, Inc. (PVCT) — 10-Q Filings
All 10-Q filings from Provectus Biopharmaceuticals, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Provectus Biopharma's Losses Widen Amid Plummeting Cash Reserves
— Nov 13, 2025 Risk: high
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported a net loss of $4,337,312 for the nine months ended September 30, 2025, a significant increase from the $2,365 -
Provectus Biopharma Files Q2 2025 10-Q
— Aug 14, 2025 Risk: medium
Provectus Biopharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The filing details financial performance and operational updates for the -
Provectus Biopharma Files Q1 2025 10-Q
— May 14, 2025 Risk: medium
Provectus Biopharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the -
Provectus Biopharma Files Q3 2024 10-Q Report
— Nov 12, 2024 Risk: medium
Provectus Biopharmaceuticals, Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, based in Knoxville, TN, operates in the Pharm -
Provectus Biopharma Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Provectus Biopharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the -
Provectus Biopharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024
— May 14, 2024 Risk: low
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Provectus Biopharmaceuticals, Inc. filed a 10-Q report f
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX